Headquartered in Los Angeles, California, SP Investment Fund invests in social positive investments in affordable housing and in emerging technology companies that solve big problems. One such emerging technology company that SP has invested in is SF17 Therapeutics, which recently changed its name to Synkrino.
Synkrino leverages artificial intelligence to develop precision immune therapies. The company uses patient-generated data to develop targeted treatments for both complex auto-inflammatory and auto-immune diseases. It was part of Y Combinator’s 2018 cohort and even joined the CITRIS Foundry portfolio of science companies that same year.
CITRIS Foundry is a highly competitive program by UC Berkeley that helps innovators make an impact in the world. The innovation hub selects a committed group of entrepreneurs every year and gives them access to the university’s resources, enabling them to leapfrog their innovations from conception to commercialization.
The program only admits transformative technologies with the potential to affect their industries positively. The program provides entrepreneurs with access to UC Berkeley’s specialized laboratories, on-campus workspace to accommodate growing teams, and direct support from Foundry Fellows drawn from the Haas School of Business, College of Engineering.
Since its founding in 2013, CITRIS Foundry has supported 65 projects and raised more than $100 million. Other companies chosen alongside Synkrino in the CITRIS Foundry 2018 group were Threestone Analytics and Corshell Technologies.
No comments:
Post a Comment